Bladder Cancer Clinical Trial Monitor — NMIBC, MIBC & Urothelial Carcinoma

The urothelial cancer trial landscape in 2026

Bladder and urothelial cancer has seen more treatment advances in the past five years than in the preceding two decades. Enfortumab vedotin + pembrolizumab (EV/pembro) has displaced platinum-based chemotherapy as the preferred first-line standard for metastatic urothelial carcinoma, based on EV-302/KEYNOTE-A39 data showing superior OS and PFS. With that paradigm established, the entire clinical development landscape has reorganized around three questions: what comes after EV/pembro, how to move curative intent into MIBC with bladder preservation, and how to address BCG-unresponsive NMIBC without systemic therapy.

The database currently shows 284 active trials and 40 active Phase 3 programs in bladder/urothelial cancer — one of the most competitive oncology spaces in 2026.

Key Phase 3 programs active in 2026

Selected active Phase 3 clinical programs as of March 2026 (data from ClinicalTrials.gov):

Metastatic urothelial carcinoma: the post-EV/pembro era

EV-302/KEYNOTE-A39 established enfortumab vedotin + pembrolizumab as the first-line standard across cisplatin-eligible and ineligible patients. With 47% objective response rate and superior OS over gem/platin, EV/pembro has become the reference point for every new first-line trial. The competitive landscape now has two distinct battlegrounds:

Challenge 1: first-line competitors to EV/pembro

Multiple programs are testing if a different ADC + IO backbone can match or exceed EV/pembro in the frontline:

• Dato-DXd + carboplatin or cisplatin (Daiichi Sankyo, NCT07129993) — TROP2-targeting ADC with exatecan payload in 1L metastatic UC. Active Phase 3 recruitment as of September 2025.
• Disitamab vedotin (RC48) + pembrolizumab vs. platinum chemo (Seagen/Pfizer, NCT05911295) — HER2-targeted ADC in HER2-expressing untreated UC. Approximately 25–30% of urothelial tumors overexpress HER2, providing a biomarker-selected population.
• SHR-A2102 + adebrelimab (Suzhou Suncadia, NCT07393542) — Chinese Phase 3 program with a novel ADC in locally advanced/metastatic urothelial carcinoma. Recruiting since February 2026.

Challenge 2: second-line after EV/pembro failure

The hardest trial design problem in urothelial oncology: what to give patients after progressing on an Nectin-4 ADC + anti-PD-1. Active strategies:

• Izalontamab brengitecan (BMS-986470, BMS, NCT07106762) — HER2×HER3 bispecific ADC (topoisomerase I payload) vs. platinum-based chemotherapy in post-IO UC. Phase 2/3 trial launched September 2025. BMS positioning this as a differentiated approach given non-Nectin-4 target.
• MK-2870 (sacituzumab tirumotecan, NCT07419295) — Merck's TROP2-targeting ADC with exatecan payload. A dedicated Phase 3 in urothelial cancer (MK-2870-031) opened March 2026, adding to MK-2870's concurrent Phase 3 expansion across 6+ tumor types.
• FGFR3 inhibitors (erdafitinib, vepugratinib) — for FGFR3-altered patients (~20% of UC) who progress on EV/pembro. Lilly's vepugratinib (LY3866288) Phase 3 in FGFR-altered urinary tract cancer is actively recruiting (NCT07218380, launched December 2025).
• BT8009 (BicycleTx, Duravelo-2, NCT06225596) — Bicycle Toxin Conjugate targeting Nectin-4 (same antigen as enfortumab vedotin, different mechanism). Phase 3 Duravelo-2 recruiting since January 2024.

Novel ADC landscape in urothelial cancer

Urothelial carcinoma has become one of the most ADC-saturated tumor types, with at least 6 distinct ADC mechanisms in Phase 2/3:

• Nectin-4 ADCs: Enfortumab vedotin (approved, Pfizer/Astellas), BT8009 (BicycleTx — Bicycle Toxin Conjugate, not classical ADC)
• TROP2 ADCs: Sacituzumab govitecan, MK-2870 (sacituzumab tirumotecan, exatecan payload), Dato-DXd
• HER2 ADCs: Disitamab vedotin (RC48, Seagen/Pfizer)
• HER2×HER3 bispecific ADC: Izalontamab brengitecan (BMS)

The ADC convergence raises a key question: with multiple payloads and linker technologies targeting overlapping antigens, will cross-resistance after EV/pembro limit subsequent ADC efficacy? This is a central concern driving sequencing studies.

Non-muscle-invasive bladder cancer (NMIBC): BCG and beyond

NMIBC — particularly BCG-unresponsive high-grade disease — has attracted more investment than any other bladder cancer sub-setting. BCG supply shortages and unmet need in BCG-unresponsive CIS (historically ~50% recurrence within 12 months) have driven a wave of intravesical programs.

TAR-200: Janssen's sustained-release intravesical platform

TAR-200 is a device-drug system that releases gemcitabine continuously into the bladder over several weeks. Janssen has built a comprehensive NMIBC clinical program:

• TAR-200 alone vs. intravesical chemo in BCG-unresponsive HR-NMIBC (NCT06211764) — pivotal Phase 3, active not recruiting. BCG-unresponsive CIS and papillary disease. TAR-210 (updated device version) vs. intravesical chemo (NCT06319820) is now also recruiting.
• TAR-200 + cetrelimab vs. BCG in BCG-naive HR-NMIBC (NCT05714202) — testing if sustained gemcitabine + anti-PD-1 can replace BCG as the HR-NMIBC standard. Active Phase 3, not recruiting.
• TAR-200 vs. intravesical chemo in recurrent HR-NMIBC after BCG (NCT06919965) — recruiting since September 2025, TAR-210 device iteration.

If TAR-200 pivotal data reads out positively, Janssen will have disrupted the BCG standard in both BCG-naive and BCG-unresponsive HR-NMIBC simultaneously.

CG Oncology: oncolytic adenovirus programs

• Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive NMIBC (Phase 3, NCT04452591) — active Phase 3 in CIS ± papillary disease. CG0070 is an oncolytic adenovirus armed with GM-CSF, selectively replicating in Rb-pathway-deficient tumor cells.
• Cretostimogene adjuvant in intermediate-risk NMIBC (NCT06111235) — separate Phase 3 in IR-NMIBC after TURBT. Recruiting launched December 2023.

Nadofaragene firadenovec expansion

Nadofaragene firadenovec (Adstiladrin, Ferring) is approved for BCG-unresponsive HR-NMIBC with CIS. Ferring is expanding the indication with two new Phase 3 trials (NCT06510374 — intermediate-risk NMIBC; NCT06545955 — BCG-unresponsive combinations with chemo or immunotherapy), both launched in October 2024.

Intravesical gemcitabine programs

• BCG + gemcitabine vs. BCG alone (Alliance for Clinical Trials, NCT07000084) — recurrent NMIBC after prior BCG, testing if adding gemcitabine to re-induction BCG improves outcomes. Recruiting July 2025.
• GEMDOCE vs. BCG in NMIBC (ECOG-ACRIN, NCT05538663) — intravesical gemcitabine-docetaxel vs. BCG. This comparison directly tests an already-widely-used regimen against the BCG standard.
• NDV-01 (sustained-release gemcitabine-docetaxel, Relmada, NCT07464145) — Phase 3 NMIBC trial opening June 2026.
• TARA-002 (OK-432, Protara, NCT07480356) — Phase 3 vs. intravesical chemo in BCG-naive HR-NMIBC. Opening May 2026.

Muscle-invasive bladder cancer (MIBC): perioperative strategies and bladder preservation

MIBC (T2–T4a) historically requires radical cystectomy with neoadjuvant cisplatin-based chemotherapy (MVAC or gem/cis). Two parallel trends are changing the landscape: immunotherapy-based perioperative combinations, and organ-preserving bladder preservation strategies.

Perioperative immunotherapy programs

• NIAGARA-2 (AstraZeneca, NCT06960577) — perioperative durvalumab + ddMVAC or gem/cis in resectable MIBC. Recruiting since May 2025. Builds on NIAGARA (durvalumab + GC in UC) data. Tests if adding anti-PD-L1 to standard neoadjuvant chemo improves pCR and OS.
• Durvalumab + gem/cis neoadjuvant + durvalumab adjuvant (NCT03732677) — AstraZeneca Phase 3 in MIBC (launched 2018), still active.
• Nivolumab + BMS-986205 (IDO1 inhibitor) perioperative (CheckMate 274 expansion, BMS NCT03661320) — still active Phase 3.
• ctDNA-guided atezolizumab adjuvant (Roche, NCT04660344) — post-cystectomy ctDNA-positive patients receive atezolizumab vs. placebo. Precision immunotherapy selection using liquid biopsy. Active Phase 3.
• MODERN: ctDNA-guided adjuvant IO (NCI, NCT05987241) — similar ctDNA-guided adjuvant design. Recruiting since February 2024.

Bladder preservation: the emerging frontier

For select MIBC patients, bladder-sparing strategies (trimodality therapy: maximal TURBT + chemoradiotherapy) have long been an option. The entry of EV/pembro into MIBC now opens a new preservation approach:

• NCT07475806 (Astellas) — Phase 2 trial directly comparing enfortumab vedotin + pembrolizumab versus radical cystectomy in MIBC patients who choose bladder preservation. Opening March 2026. This is the first prospective comparison of EV/pembro to surgery as a preservation strategy.
• TAR-200 + cetrelimab vs. chemoradiotherapy in MIBC (Janssen, NCT04658862) — intravesical sustained-release gem device + anti-PD-1 vs. concurrent CRT for MIBC bladder preservation. Active Phase 3.
• ARCHER (NRG Oncology, NCT07097142) — hypofractionated vs. standard radiation with chemotherapy for MIBC. Tests if shorter radiation duration (fewer treatment visits) is non-inferior. Recruiting since May 2026.
• Enfortumab vedotin + pembro + selective bladder sparing (Matthew Galsky/MSKCC, NCT06809140) — Phase 2 EV/pembro combined with selective cystectomy guided by pathologic response. Recruiting since April 2025.

The bladder preservation question is becoming one of the defining clinical controversies in MIBC: with EV/pembro achieving high pathologic complete response rates in neoadjuvant MIBC trials, the question of whether surgery remains necessary for patients who achieve pCR will define cystectomy's future role.

FGFR3 landscape: expanding targeted therapy

FGFR3 alterations (mutations + fusions) occur in ~15–20% of metastatic UC and ~70–80% of NMIBC. Erdafitinib (Balversa, Janssen) is approved for FGFR3-altered UC post-platinum. Two approaches are expanding the FGFR3 opportunity:

• Vepugratinib (LY3866288, Eli Lilly, NCT07218380) — next-generation selective FGFR inhibitor in Phase 3 for FGFR-altered urinary tract cancer. Recruiting since December 2025. Designed for improved selectivity and reduced ocular toxicity compared to erdafitinib.
• Erdafitinib vs. vinflunine/docetaxel/pembrolizumab (Janssen, NCT03390504) — Phase 3 LIGHT study still active. Also testing erdafitinib in FGFR3-altered patients post-EV/pembro failure.
• KEYMAKER-U04 Substudy D (Merck, NCT07232602) — MK-2870 + enfortumab vedotin + pembrolizumab combination in UC. Tests whether adding TROP2 ADC to EV/pembro backbone improves outcomes. Recruiting February 2026.

Who monitors bladder cancer clinical trials?

• Urothelial oncology pharma teams — companies with NMIBC intravesical programs (Janssen, Ferring, CG Oncology, Relmada, Protara) tracking competitor enrollment status
• Clinical development groups designing post-EV/pembro second-line and MIBC perioperative trials, monitoring what the competition is testing
• Medical affairs and MSL teams at Pfizer/Astellas, Merck, BMS, Daiichi Sankyo tracking trial openings for HCP conversations
• Healthcare investors covering CG Oncology, BicycleTx, UroGen, and other urothelial-focused biotech companies
• Academic urologic oncologists and GU oncology fellows reviewing what trials are available for referral at their centers

Frequently asked questions

What is the current standard of care for metastatic urothelial carcinoma?

Enfortumab vedotin + pembrolizumab (EV/pembro) is the preferred first-line treatment for cisplatin-eligible and cisplatin-ineligible metastatic urothelial carcinoma as of 2026, based on EV-302/KEYNOTE-A39 data showing superior overall survival over platinum-based chemotherapy. Platinum-based regimens (gem/cis or gem/carbo) remain options for patients who cannot tolerate EV/pembro toxicity.

What are the most active Phase 3 trials in bladder cancer?

Over 40 Phase 3 programs are active in bladder/urothelial cancer in 2026. Key recruiting trials include NIAGARA-2 (AstraZeneca perioperative MIBC), Dato-DXd first-line UC (Daiichi Sankyo), izalontamab brengitecan post-IO (BMS), vepugratinib for FGFR-altered UC (Lilly), and TAR-200 programs for NMIBC (Janssen).

What treatments are being studied for BCG-unresponsive NMIBC?

BCG-unresponsive NMIBC has multiple active Phase 3 programs: TAR-200 intravesical sustained-release gemcitabine (Janssen), cretostimogene grenadenorepvec oncolytic adenovirus (CG Oncology), nadofaragene firadenovec combinations (Ferring), NDV-01 (Relmada), and TARA-002 (Protara). Systemic pembrolizumab (approved) and combination BCG + gemcitabine (Alliance) are also being evaluated.

Is bladder preservation being studied as an alternative to radical cystectomy?

Yes. Several trials are now directly comparing bladder-preserving strategies to cystectomy in MIBC: NCT07475806 (Astellas, EV/pembro vs. radical cystectomy), TAR-200 + cetrelimab vs. chemoradiotherapy (Janssen), and multiple neoadjuvant EV/pembro trials exploring whether high pCR rates can make selective organ preservation safe.

Related GU oncology and urothelial cancer trial monitors

• Prostate cancer clinical trials — shared urologic oncology infrastructure and overlapping immunotherapy programs
• Kidney cancer clinical trials — related GU oncology and overlapping IO/TKI programs
• ADC clinical trials — enfortumab vedotin, disitamab vedotin, izalontamab brengitecan, MK-2870 competitive landscape
• Melanoma clinical trials — overlapping checkpoint inhibitor programs
• Pharma pipeline tracker — Pfizer, AstraZeneca, Merck, BMS, Daiichi Sankyo pipeline overview